Literature DB >> 22247807

Long-term recurrence-free survival in a patient with stage IVB uterine carcinosarcoma.

Gun Yoon1, Yong-Seok Kim, Byoung-Gie Kim, Duk-Soo Bae, Jeong-Won Lee.   

Abstract

Uterine carcinosarcomas are rare and highly aggressive tumors with a poor prognosis. Due to early metastasis and disease progression, it is known to be far more aggressive than matched grade 3 endometroid endometrial carcinomas. Five-year survival for stage IV is reported to be 10% and overall survival for stage IVB is expected to be very poor. The authors report one case after experiencing long-term survival (over 5 years) for stage IVB carcinosarcoma of uterus. Total abdominal hysterectomy and bilateral salpingo-oophorectomy was performed to 56 year old patient for uterine myoma. On pathology report, uterine carcinosarcoma was diagnosed and image studies were performed. With the impression of stage IVB uterine carcinosarcoma, 6 cycles of chemotherapy (ifosfamide and cisplatin) was conducted as adjuvant. Up to recently (over 5 years), she maintains good performance scale without evidence of tumor recurrence or disease progression.

Entities:  

Keywords:  Long-term survival; Uterine carcinosarcoma

Year:  2011        PMID: 22247807      PMCID: PMC3254849          DOI: 10.3802/jgo.2011.22.4.292

Source DB:  PubMed          Journal:  J Gynecol Oncol        ISSN: 2005-0380            Impact factor:   4.401


  5 in total

1.  Phase III trial of ifosfamide with or without paclitaxel in advanced uterine carcinosarcoma: a Gynecologic Oncology Group Study.

Authors:  Howard D Homesley; Virginia Filiaci; Maurie Markman; Pincas Bitterman; Lynne Eaton; Larry C Kilgore; Bradley J Monk; Frederick R Ueland
Journal:  J Clin Oncol       Date:  2007-02-10       Impact factor: 44.544

2.  Phase II trial of ifosfamide and mesna in mixed mesodermal tumors of the uterus (a Gynecologic Oncology Group study).

Authors:  G P Sutton; J A Blessing; N Rosenshein; G Photopulos; P J DiSaia
Journal:  Am J Obstet Gynecol       Date:  1989-08       Impact factor: 8.661

3.  A gynecologic oncology group randomized phase III trial of whole abdominal irradiation (WAI) vs. cisplatin-ifosfamide and mesna (CIM) as post-surgical therapy in stage I-IV carcinosarcoma (CS) of the uterus.

Authors:  Aaron H Wolfson; Mark F Brady; Thomas Rocereto; Robert S Mannel; Yi-Chun Lee; Robert J Futoran; David E Cohn; Olga B Ioffe
Journal:  Gynecol Oncol       Date:  2007-09-05       Impact factor: 5.482

4.  Uterine carcinosarcomas and grade 3 endometrioid cancers: evidence for distinct tumor behavior.

Authors:  Nisha Bansal; Thomas J Herzog; Venkatraman E Seshan; Peter B Schiff; William M Burke; Carmel J Cohen; Jason D Wright
Journal:  Obstet Gynecol       Date:  2008-07       Impact factor: 7.661

5.  Malignant mixed Müllerian tumors of the uterus: analysis of patterns of failure, prognostic factors, and treatment outcome.

Authors:  Michael Callister; Lois M Ramondetta; Anuja Jhingran; Thomas W Burke; Patricia J Eifel
Journal:  Int J Radiat Oncol Biol Phys       Date:  2004-03-01       Impact factor: 7.038

  5 in total
  1 in total

1.  Investigating the Role of Telomere and Telomerase Associated Genes and Proteins in Endometrial Cancer.

Authors:  Alice Bradfield; Lucy Button; Josephine Drury; Daniel C Green; Christopher J Hill; Dharani K Hapangama
Journal:  Methods Protoc       Date:  2020-09-03
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.